19 June 2013
Keywords: fda, panel, recommends, approval, biologic, xolair, asthma
Article | 26 May 2003
Xolair (omalizumab) has been unanimously recomended for approval by the US Food and Drug Administration's Pulmonary Allergy Drugs Advisory
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 June 2003
26 May 2003
30 June 2003
© 2013 thepharmaletter.com